Researchers Target Zolmitriptan Dosing for Pediatric Migraine

This article originally appeared here.
Share this content:
Researchers Target Zolmitriptan Dosing for Pediatric Migraine
Researchers Target Zolmitriptan Dosing for Pediatric Migraine

THURSDAY, June 8, 2017 (HealthDay News) -- In a report published online June 5 in the Journal of Clinical Pharmacology, recommended dosing regimens of zolmitriptan are suggested for children with migraine.

Wangda Zhou, Ph.D., from AstraZeneca Pharmaceuticals in Waltham, Mass., and colleagues developed a population pharmacokinetic model for zolmitriptan and its active metabolite in adults and adolescents, and provided appropriate dosing regimens for use in clinical trials in 6- to 11-year-old children. Data from a single-dose study involving 5.0-mg zolmitriptan nasal spray (ZNS) conducted in adult and adolescents with migraine were applied.

The researchers found that adults and adolescents had similar plasma concentration profiles of zolmitriptan and its metabolite 183C91. The estimated typical apparent volume of distribution and clearance of zolmitriptan were 136 L and 121 L/h, respectively; between-subject variability was 56.5 and 42.6 percent, respectively. To achieve exposures similar to those of the adult and adolescent population administered 5.0 mg ZNS, a body-weight dosing scheme of 5.0 and 2.5 mg ZNS is recommended in children greater than and less than 50 kg, respectively.

"The recommended doses for children to achieve exposure similar to that observed in adults given 2.5 mg ZNS are 2.5 mg (≥50 kg) and 1.0 mg (15 to 50 kg)," the authors write. "These dosing regimens could be used in future clinical trials."

The authors disclosed financial ties to AstraZeneca, a manufacturer of zolmitriptan.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

ACG: Diphenhydramine Ups Sedation in Chronic Opioid Users

ACG: Diphenhydramine Ups Sedation in Chronic Opioid Users

Improvement in sedation scores for patients using chronic opioids scheduled to undergo colonoscopy

Online Ratings Not Aligned With Objective Quality Measures

Online Ratings Not Aligned With Objective Quality Measures

In addition, consumer ratings are consistent across platforms for specialist physicians

Most Female Physicians Have Faced Sexist Patient Comments

Most Female Physicians Have Faced Sexist Patient Comments

Sexual harassment by patients can negatively affect physician-patient relationship, quality of care

is free, fast, and customized just for you!

Already a member?

Sign In Now »